Opus Genetics is trading 5.67% higher at $4.04 in pre-market on October 23, with no clear company-specific catalyst identified. - Compared with the October 22 close of $3.82. - An October 23-dated page recirculates an ARVO 2026 data announcement, but the underlying press release was dated May 7, so it does not establish a new catalyst. - The company’s latest listed releases include an October 21 FDA IND clearance announcement.